Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropeginterferon alfa-2b + nivolumab
- Development stage
- Unknown
- Lead developer
- PharmaEssentia
- Modality
- Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
ropeginterferon alfa-2b + nivolumab is an investigational combination therapy being developed by PharmaEssentia for the treatment of hepatocellular carcinoma (HCC), particularly HBV-related HCC. The regimen consists of ropeginterferon alfa-2b (P1101), a novel, long-acting, mono-pegylated proline interferon, administered sequentially with nivolumab, an anti-PD-1 monoclonal antibody. Ropeginterferon alfa-2b acts as an agonist at the interferon alfa receptor (IFNAR), providing immune and antiproliferative effects, while nivolumab functions as an immune checkpoint inhibitor by blocking the PD-1 receptor. This combination is designed to enhance antitumor immunity and has demonstrated synergistic effects in suppressing HBV. It is currently being evaluated in Phase 1/2 clinical trials as an adjuvant treatment to prevent HCC recurrence following curative surgery.
- Other names
- ropeginterferon alfa-2b + PD-1 inhibitorRopeg + anti-PD-1
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ropeginterferon alfa-2b + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropeginterferon alfa-2b + nivolumab.